Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (not Bio Green Med Solution, Inc.) for the reporting period ending December 24, 2009. The company is incorporated in Delaware and maintains its principal executive offices in Berkeley Heights, New Jersey.
Key Financial Metrics
The filing reports a specific equity financing transaction rather than comprehensive financial statements.
- Capital Raised: $1,030,000 in funds drawn down.
- Shares Issued: 1,254,574 shares of common stock.
- Counterparty: Kingsbridge Capital Limited.
- Instrument: Committed Equity Financing Facility (CEFF) dated December 10, 2007, as amended.
The filing text does not provide clear values for revenue, profit, cash flow, margins, total debt, or liquidity positions outside of this specific transaction.
Material Changes
The material change reported is the unregistered sale of equity securities under Item 3.02. The company sold the aforementioned shares to Kingsbridge Capital Limited in consideration for the funds drawn from the CEFF. The transaction relied on the exemption from registration contained in Section 4(2) of the Securities Act of 1933 and Rule 506.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the unregistered sale of securities. No unusual items or contingencies are detailed in this report.
Investor Verification Checklist
- Verify the current status and remaining capacity of the Committed Equity Financing Facility (CEFF) with Kingsbridge Capital Limited.
- Confirm the total number of outstanding shares post-issuance to assess dilution impact.
- Review the full terms of the CEFF agreement dated December 10, 2007, as amended, for any covenants or restrictions triggered by this drawdown.
- Check subsequent filings for the company's actual cash burn rate and runway, as this 8-K only confirms the inflow of $1,030,000.